Bavarian Nordic A/S:
Vaccines for infectious diseases and oncology. Recently won FDA approval of JYNNEOS for prevention of smallpox & monkeypox, including in high-risk, immunocompromised populations. Also included in its portfolio of wholly-owned and Big Pharma-partnered products, is first broad spectrum vaccine in development for RSV—MVA-BN-RSV—which successfully concluded Ph 2 development, with a Ph 3 trial anticipated to start in 2020. Other vaccine candidates include Ebola, HPV, HBV and HIV, which are being developed through strategic partnership with Janssen. The Company is also advancing vaccine candidate for solid tumors including chordoma -- a rare bone tumor that develops along the spine for which there is currently no available treatment options.
Phase III, Phase l or ll
Immunotherapy, Infectious Disease, Oncology
500MM - 1B
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Stock Market Data
Market Data copyright © 2019 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by